TSRX Share Price

Open 13.68 Change Price %
High 13.76 1 Day -0.05 -0.37
Low 13.63 1 Week 0.00 0.00
Close 13.63 1 Month 0.00 0.00
Volume 5890879 1 Year 0.00 0.00
52 Week High 192.94
52 Week Low 36.68
TSRX Important Levels
Resistance 2 13.75
Resistance 1 13.70
Pivot 13.67
Support 1 13.56
Support 2 13.51
NASDAQ USA Most Active Stocks
SPWR 8.98 1.01%
TFSL 17.20 0.17%
RIGL 2.52 9.57%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
FNFG 10.18 -0.20%
REGN 373.05 3.34%
DELL 13.86 0.22%
More..
NASDAQ USA Top Gainers Stocks
TEAR 5.74 983.02%
CGEI 0.37 85.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
IMGN 3.28 21.03%
VOXX 5.05 20.24%
HAUP 0.06 20.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Trius Therapeutics, Inc. (NASDAQ: TSRX)

TSRX Technical Analysis 5
As on 11th Sep 2013 TSRX Share Price closed @ 13.63 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 7.41 & Strong Buy for SHORT-TERM with Stoploss of 11.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
TSRX Target for February
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TSRX Other Details
Segment EQ
Market Capital 209083728.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
TSRX Address
TSRX
N/A
TSRX Latest News
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of Trius ...   PR Newswire (press release)   - 15th Aug 16
Cubist Pharmaceuticals Completes Acquisition of Trius Therapeutics   EON: Enhanced Online News (press release)   - 12th Sep 13
Trius Therapeutics, Inc. (TSRX) Investor Lawsuit to Halt Takeover Announced by ...   GlobeNewswire (press release)   - 05th Aug 13
Trius Therapeutics To Be Acquired By Cubist   Seeking Alpha   - 31st Jul 13
Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID ...   GlobeNewswire (press release)   - 23rd Apr 13
Trius Announces Positive Results From ESTABLISH 2 Study of Tedizolid in Severe ...   GlobeNewswire (press release)   - 25th Mar 13
Trius Therapeutics: Takeover Candidate In 2013   Seeking Alpha   - 04th Feb 13
Trius Therapeutics: Tedizolid's Potential Commercial Paths   Seeking Alpha   - 05th Dec 12
Pfizer And Teva Settlement On Generic Zyvox A Significant Positive For Trius ...   Seeking Alpha   - 01st Nov 12
Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and ...   GlobeNewsWire (press release)   - 27th Jul 11
Interactive Technical Analysis Chart Trius Therapeutics, Inc. ( TSRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Trius Therapeutics, Inc.
TSRX Business Profile
Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.